Results 21 to 30 of about 3,628 (221)
Scientific Reports, 2023 Cangrelor, the first intravenous P2Y12 inhibitor (P2Y12-I), has been approved on the basis of three large RCTs from the CHAMPION program which nevertheless have been criticized for the low bleeding risk of the enrolled patients, the large quote of ...
Martino Pepe +12 more
doaj +1 more source
Stroke: Vascular and Interventional Neurology, 2023 Background Procedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. We aimed to compare the safety profile of low‐dose intravenous cangrelor versus dual oral antiplatelet ...
Aaron Rodriguez‐Calienes +24 more
doaj +1 more source
Cangrelor for the management and prevention of arterial thrombosis [PDF]
, 2016 INTRODUCTION: Despite advances in antiplatelet therapy, the optimum antithrombotic regimen during percutaneous coronary intervention (PCI) remains to be determined.
Sinha, A., Storey, R.F.
core +1 more source
American Heart Journal Plus, 2021 Background: Peripheral artery disease (PAD) is associated with an increased risk of ischemic events following percutaneous coronary intervention (PCI). More aggressive antiplatelet therapy may mitigate this risk.
J. Antonio Gutierrez +13 more
doaj +1 more source
Interdisciplinary Neurosurgery, 2021 Ruptured blister type aneurysms are challenging to treat, and the ideal treatment remains debated. Recently, endovascular procedures, particularly flow diversion, gained popularity in treating blister aneurysms; however, the need for dual antiplatelet ...
Taylor Anne Wilson +2 more
doaj +1 more source
Cangrelor in STEMI as a bridge to CABG- a mini-case series
American Heart Journal Plus, 2022 Background: Patients with STEMI receive dual antiplatelet therapy as soon as possible with aspirin and a P2Y12 receptor antagonist prior to PCI. A fraction of these patients may have multi-vessel disease needing emergent CABG surgery.
Bishesh Shrestha +4 more
doaj +1 more source
P2Y12 platelet receptors: importance in percutaneous coronary intervention [PDF]
, 2013 Apart from their role in hemostasis and thrombosis, platelets are involved in many other biological processes such as wound healing and angiogenesis. Percutaneous coronary intervention is a highly thrombogenic procedure inducing platelets and monocytes ...
Alves, Claudia Maria Rodrigues +5 more
core +4 more sources
TH Open, 2020 Objective The aim of the study is to describe the real-world use of the P2Y12 inhibitor cangrelor as a bridging strategy in patients at high thrombotic risk after percutaneous coronary intervention (PCI) and referred to surgery requiring perioperative ...
Roberta Rossini +19 more
doaj +1 more source
Human platelet activation by Escherichia coli: roles for FcγRIIA and integrin αIIbβ3 [PDF]
, 2016 Gram-negative Escherichia coli cause diseases such as sepsis and hemolytic uremic syndrome in which thrombotic disorders can be found. Direct platelet–bacterium interactions might contribute to some of these conditions; however, mechanisms of human ...
Arman, Mònica +5 more
core +4 more sources
GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors [PDF]
, 2008 Background GPR17 is a G-protein-coupled receptor located at intermediate phylogenetic position between two distinct receptor families: the P2Y and CysLT receptors for extracellular nucleotides and cysteinyl-LTs, respectively.
Chiara Parravicini +3 more
core +3 more sources